- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
5 result(s) found for: Dengue hemorrhagic fever.
Displaying page 1 of 1.
| EudraCT Number: 2019-000994-22 | Sponsor Protocol Number: CYD71 | Start Date*: 2019-06-13 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico | ||
| Medical condition: Dengue Fever Dengue Hemorrhagic Fever Human Papillomavirus Disease | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2019-000993-44 | Sponsor Protocol Number: CYD63 | Start Date*: 2019-06-13 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore | ||
| Medical condition: Dengue Fever Dengue Hemorrhagic Fever | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2019-003136-23 | Sponsor Protocol Number: CYD66 | Start Date*: 2020-02-12 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines | ||
| Medical condition: Dengue Fever Dengue Hemorrhagic Fever | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2020-002854-25 | Sponsor Protocol Number: CYD65 | Start Date*: 2020-09-13 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3-Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years after the L... | ||
| Medical condition: Dengue Fever Dengue Hemorrhagic Fever | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2019-003135-36 | Sponsor Protocol Number: CYD67 | Start Date*: 2019-10-31 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia | ||
| Medical condition: Dengue Fever Dengue Hemorrhagic Fever Human Papillomavirus Disease | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.